Skip to content

Remdesivir Conflicts and Craven Hospital Conduct

Day 1 · 3:18:20 · Ron Johnson

  • 💵 Guideline panelists held undisclosed Gilead ties; endpoints shifted from death to “days to recovery.”
  • 🚫 WHO and Ebola data already showed remdesivir harmed; a surgeon was told not to give it to a “nice girl.”
  • ✝️ Families report last rites withheld unless remdesivir was accepted—conduct Johnson calls evil.

Financial capture and coercive hospital practices around remdesivir.

← Q&A: How Did Emergency Orders Bypass Normal Safety Proof? | Q&A: How Should Doctors Reckon With What They Did? →

Transcript

Ron Johnson · 3:18:20

Let me just quick, uh, point out the hypocrisy of Fauci when it comes to remdesivir. This is, uh, an email sent on March 18, 2020. This is 18 days after Peter Mark's already found out that, uh, you know, we got safety, you know, we got a problem with the algorithm. But on a different issue, he's writing to Robert Redfield, then the director of the CDC, and he's trying— he's comparing remdesivir to hydroxychloroquine. He says we need to link remdesivir to a much more strict protocol as opposed to hydroxychloroquine, which is an approved drug, and although it does have some adverse event, events. We have tons of experience with it. That's a complete— I mean, they have the Surgisphere study, which was completely fraudulent, which, you know, they published here. It tanked hydroxychloroquine together with what Rick Bright did for it. Uh, and, but, but here Fauci is, you know, saying, you know, we've got a lot of experience hydroxychloroquine, uh, but we really need to be a little more careful with remdesivir.

Ron Johnson · 3:19:24

All of a sudden, remdesivir just became the drug to use, right? It was manufactured by Gilead, made a lot of money for Gilead. Uh, in an interview of Sheryl Atkinson, Full Measure, she's talking to Dr. Jane Orient and also Stephen Hadfield, and Sheryl says it turns out one author of the report— so they did a study on, on remdesivir, and in the middle of the study they changed the endpoint from death because it had no impact on death to days to recovery, which apparently for whatever reason, whether that is true or not, the Remdesivir showed, you know, less days to recovery. Turns out one of the authors of the report issued by HHS received research funding from Gilead, the maker of Remdesivir, including a $247,000 grant. Uh, she goes on, we checked financial ties among experts on the government panel to devise advising coronavirus treatment guidelines. We found 11 members reporting links to a drug company, 9 of them named relationships to remdesivir's maker Gilead.

Ron Johnson · 3:20:30

7 More, including 2 of the committee's leaders, have ties to Gilead beyond the 11 months they chose to disclose. So gee, you think there's a conflict of interest and all of a sudden rushing remdesivir to get emergency use authorization, even though the WHO recommends against the use of it? They stopped using it in Ebola trial because it killed the subjects faster than the protocol without remdesivir. Now I'll close up and on my remdesivir rant, uh, one of the witnesses for hospital protocols, uh, he's a staff surgeon at Providence Regional Medical Center in Everett, Washington, and he, he, one of the courageous doctors that came to help out during COVID And, uh, he said, after our hospital was given remdesivir by CDC, we were provided misleading, inaccurate information about the drug by medical leadership. When I had a young trauma patient who was a perfect candidate according to their protocols for remdesivir, the infectious disease doctor on call told me to not give it to her because, quote, she seems like a nice girl.

Ron Johnson · 3:21:33

He concludes it was known early that remdesivir kills. That was the standard of care.